LXEO vs. COGT, PAHC, RLAY, CDMO, SANA, TYRA, SEPN, AVDL, IMTX, and CRON
Should you be buying Lexeo Therapeutics stock or one of its competitors? The main competitors of Lexeo Therapeutics include Cogent Biosciences (COGT), Phibro Animal Health (PAHC), Relay Therapeutics (RLAY), Avid Bioservices (CDMO), Sana Biotechnology (SANA), Tyra Biosciences (TYRA), Septerna (SEPN), Avadel Pharmaceuticals (AVDL), Immatics (IMTX), and Cronos Group (CRON). These companies are all part of the "pharmaceutical products" industry.
Lexeo Therapeutics vs.
Cogent Biosciences (NASDAQ:COGT) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations, media sentiment and community ranking.
In the previous week, Cogent Biosciences had 16 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 17 mentions for Cogent Biosciences and 1 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.83 beat Cogent Biosciences' score of 0.28 indicating that Lexeo Therapeutics is being referred to more favorably in the news media.
Cogent Biosciences presently has a consensus price target of $14.33, indicating a potential upside of 78.50%. Lexeo Therapeutics has a consensus price target of $23.80, indicating a potential upside of 369.43%. Given Lexeo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Lexeo Therapeutics is more favorable than Cogent Biosciences.
Cogent Biosciences received 269 more outperform votes than Lexeo Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Lexeo Therapeutics an outperform vote while only 70.59% of users gave Cogent Biosciences an outperform vote.
Lexeo Therapeutics has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Lexeo Therapeutics' return on equity of -57.66% beat Cogent Biosciences' return on equity.
Cogent Biosciences has a beta of 1.76, suggesting that its share price is 76% more volatile than the S&P 500. Comparatively, Lexeo Therapeutics has a beta of 3.08, suggesting that its share price is 208% more volatile than the S&P 500.
60.7% of Lexeo Therapeutics shares are held by institutional investors. 5.9% of Cogent Biosciences shares are held by company insiders. Comparatively, 4.5% of Lexeo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Lexeo Therapeutics beats Cogent Biosciences on 13 of the 17 factors compared between the two stocks.
Get Lexeo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LXEO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lexeo Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:LXEO) was last updated on 1/20/2025 by MarketBeat.com Staff
